Genmab A/S ADR (GMAB) Social Stream



Genmab A/S ADR (GMAB): $38.53

-0.40 (-1.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GMAB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Featured Post From StockTwits About GMAB

$GMAB $BOLT $ZYME $AZN $RHHBY Genmab CEO and CM (we're super excited abt the Bolt Biotherapeutics technology and platform. We are already working with them on a very large number of target programs. the partnership is a complementary strategy to the things that we have already been working on, either stand-alone or collaboration BioNTech. We have looked, at a number of companies that are working on this, and we felt that they were very much leading.
It's already clinically validated, Jonathan, in the HER2 space. This is very different from some other technology platforms. So, we are very, very excited. We have already, I think, more than several handful of potential targets we are pursuing, both at monospecific and with bispecific. So, I think there's definitely more to come here,.
I don't think we would, at this call, give any indications on targets, except that this is a very important cornerstone of our future strategy. )
https://www.fool.com/earnings/call-transcripts/2021/08/11/genmab-as-gmab-q2-2021-earnings-call-transcript/
mostbullish, published August 12, 2021

What Else are GMAB Traders Talking About?


Other tickers frequently mentioned alongside GMAB are BOLT, ZYME, AZN and RHHBY.

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4458 seconds.